Similar articles

• Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin.

  Glynne-Jones R, Meadows H, Wood W. Glynne-Jones R, et al. Clin Oncol (R Coll Radiol). 2007 Jun;19(5):327-9. doi: 10.1016/j.clon.2007.03.003. Epub 2007 Apr 16. Clin Oncol (R Coll Radiol). 2007. PMID: 17434299 No abstract available.
• Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.

  Flatmark K, Ree AH. Flatmark K, et al. J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3. doi: 10.1200/JCO.2010.30.0921. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733124 No abstract available.
• [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].

  Créhange G, Bosset JF, Maingon P. Créhange G, et al. Cancer Radiother. 2011 Oct;15(6-7):440-4. doi: 10.1016/j.canrad.2011.05.006. Epub 2011 Jul 28. Cancer Radiother. 2011. PMID: 21802334 Review. French.
• Integration of novel agents into combined-modality treatment for rectal cancer patients.

  Rödel C, Sauer R. Rödel C, et al. Strahlenther Onkol. 2007 May;183(5):227-35. doi: 10.1007/s00066-007-9000-9. Strahlenther Onkol. 2007. PMID: 17497093 Review.
• [Chemotherapy and rectal cancer].

  Michel P, Di Fiore F. Michel P, et al. Cancer Radiother. 2011 Oct;15(6-7):436-9. doi: 10.1016/j.canrad.2011.06.002. Epub 2011 Aug 31. Cancer Radiother. 2011. PMID: 21885319 Review. French.